Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-acetyl-N'-beta-D-glucopyranosyl urea is a synthetic small molecule that acts as an inhibitor of glycogen phosphorylase (muscle form). It is structurally related to glucose and contains both an acetylated urea group and a beta-D-glucopyranoside moiety. The compound has been studied for its potential as an antidiabetic agent due to its ability to inhibit glycogen phosphorylase—a key enzyme in glycogen breakdown—thereby potentially reducing hepatic glucose output. Structural studies have shown it binds at the catalytic site of muscle glycogen phosphorylase b with minimal conformational change in the protein[1][5]. It remains experimental and has not advanced beyond preclinical or early investigational stages.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-acetyl-N'-beta-D-glucopyranosyl urea.